News
Press Releases
June 24, 2025 08:30 am
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
June 10, 2025 08:30 am
Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
May 28, 2025 08:30 am
Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
May 20, 2025 08:30 am
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
May 8, 2025 08:00 am
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
April 29, 2025 08:30 am
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
April 16, 2025 07:00 am
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
April 14, 2025 08:30 am
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
April 11, 2025 08:30 am